Acromegaly Treatment Quality of Life Study

Mass General Brigham

Status: Completed

Conditions: Acromegaly

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01732406

2012P001556

Details and patient eligibility

About

The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly. At the same time, they will also be studying the effects of different acromegaly treatments on the quality of life.

Enrollment: 126 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-90
• Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin analog monotherapy

Exclusion criteria

• Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study
• Initiation or discontinuation of testosterone or estrogen within 3 months of entry
• Pregnant and nursing women

Trial design

126 participants in 3 patient groups

Acomegaly with Pegvisomant

Description:

Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.

Acromegaly with somatostatin analog

Description:

Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly

Active Acromegaly

Description:

Patients not on drugs for treatment of acromegaly